Compare

AOD-9604 vs SNAP-8

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

AOD-9604

2248 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 52% · Mixed 36% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
-165
Skin appearance
-101
Appetite control
-115
Energy
-49
Mood
-86

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
-69
Headache
-21
GI discomfort
-150
Dizziness
-54
Fatigue
-87

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–600 mcg

10–25
3
25–50
5
50–100
14
100–200
18
200–400
9
400–600
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing12stacking30side effects18aod-96046

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 495 repeat reporters

SNAP-8

133 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 24% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
152
Mood
119
Focus
137
Sleep quality
27
Lean mass
148

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
68
Fatigue
19
Nausea
102
Water retention
23
Appetite loss
148

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 200–400 mcg

Reports span 25–1000 mcg

25–50
1
50–100
4
100–200
9
200–400
24
400–600
12
600–1000
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing17stacking20side effects33snap-816

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 29 repeat reporters

Sources (8)

Published sources linked on the AOD-9604 and SNAP-8 wiki pages.

  1. PubMed

    A synthetic fragment of human growth hormone promotes lipid mobilization

    Heffernan MA, Thorburn AW, Fam B, et al. Int J Obes Relat Metab Disord. 2001

    Source
    Wiki study page →
  2. PubMed

    A synthetic human growth hormone fragment enhances proteoglycan synthesis

    Ng FM, Sun J, Sharma L, et al. Osteoarthritis Cartilage. 2010

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    AOD9604 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

    Heffernan MA, Thorburn AW, Fam B, et al. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001

    Source
    Wiki study page →
  5. PubMed

    The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

    Heffernan M, Summers RJ, Thorburn A, et al. Endocrinology. 2001

    Source
    Wiki study page →
  6. PubMed

    Acetyl hexapeptide-3 in a emulsion formulation for reduced wrinkle depth

    Raikou V, Varvaresou A, Panderi I, et al. J Cosmet Dermatol. 2009

    Source
    Wiki study page →
  7. PubMed

    Targeting lymphoid-derived IL-17 signaling to delay skin aging

    Solá P, Mereu E, Bonjoch J, et al. Nature aging. 2023

    Source
    Wiki study page →
  8. PubMed

    Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair

    Shook BA, Wasko RR, Rivera-Gonzalez GC, et al. Science (New York, N.Y.). 2018

    Source
    Wiki study page →